Cancer information / Cancer 101 / Cancer research / Chemotherapy

Cao SM, Yang Q, Guo L et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. (2017, April). European Journal of Cancer. 75:14-23.

Davidson NE, Armstrong SA, Coussens LM, et al. AACR cancer progress report 2016. (2016). Clinical Cancer Research. 22(19 Supplement):S1-S137. Retrieved from:

Faivre-Finn C, Snee M, Ashcroft L et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. (2017, August). Lancet Oncology. 18(8):1116-1125.

Glynne-Jones R, Sebag-Montefiore D, Meadows HM et al. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. (2017, March). Lancet Oncology. 18(3): 347–356.

National Cancer Institute. (2015, May 7). Research Areas: Treatment. Retrieved from:

Ringash J, Waldron JN, Siu LL et al. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). (2017, February). European Journal of Cancer. 72:192-199.

Stahl M, Walz MK, Riera-Knorrenschild J et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. (2017, August). European Journal of Cancer. 81:183-190.